Related Articles

The following related articles are available for this Editorial:
A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
Sanjay Goel, Alain C. Mita, Monica Mita, Eric K. Rowinsky, Quincy S. Chu, Nancy Wong, Christopher Desjardins, Fang Fang, Mendel Jansen, Dale E. Shuster, Sridhar Mani, and Chris H. Takimoto

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
Antoinette R. Tan, Eric H. Rubin, Diana C. Walton, Dale E. Shuster, Y. Nancy Wong, Fang Fang, Simon Ashworth, and Lee S. Rosen